Monkeypox Fast Facts

JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating)

If you have monkeypox symptoms, talk to your healthcare provider even if you haven’t had contact with someone who has monkeypox.

When properly administered, vaccines can be effective tools at protecting people against monkeypox illness.

What you need to know:

- **JYNNEOS is a vaccine approved (licensed) by the FDA** for prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This vaccine, which was approved in 2019, is the only vaccine approved for the prevention of monkeypox in the U.S. Use in populations under age 18 requires submission of a single patient Expanded Access Investigational New Drug application to the FDA.
- **JYNNEOS is approved as a two-dose vaccination series.** The Centers for Disease Control and Prevention considers people fully vaccinated about two weeks after their second shot, and it is not yet clear how well people are protected after only one dose. The CDC recommends vaccinated individuals should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has monkeypox.
- The FDA evaluation of this licensed product helps ensure the safety, effectiveness and quality of the vaccine.

About the vaccine:

- The vaccine does not contain the contain the viruses that cause smallpox or monkeypox.
- The effectiveness of JYNNEOS against monkeypox is supported studies in both humans and animals. For more information on the clinical studies see: [FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox](https://www.fda.gov/vaccines-blood-biological-products/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-monkeypox).
- JYNNEOS is made from a vaccinia virus, a virus that is closely related to, but less harmful than, smallpox or monkeypox viruses, and can protect against both diseases.
- It is given as two subcutaneous injections (shots under the skin) 28 days apart.
- The most commonly reported side effects from patients in the clinical study were pain, redness, swelling, itching, firmness at the injection site, muscle pain, headache, chills and fatigue.
- The prescribing information contains more information about the product.

Additional information:

- JYNNEOS is available from the Strategic National Stockpile and can be requested in consultation with CDC. In the U.S., there is currently a limited supply of the vaccine although more is expected in coming weeks and months.
- The CDC has recommended approaches for vaccination of certain individuals in the [CDC Vaccine Strategies to Prevent Monkeypox](https://www.cdc.gov/vaccines/schedules/downloads/professionals/immunization-schedule Monkeypox.pdf), in particular to people following exposure to monkeypox and certain higher risk individuals.

###